Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials

Abstract

IntroductionIn an attempt to improve outcomes for patients with coronavirus disease 19 (COVID-19), several drugs, such as remdesivir, hydroxychloroquine (with or without azithromycin), and lopinavir/ritonavir, have been evaluated for treatment. While much attention focuses on potential benefits of these drugs, this must be weighed against their adverse effects.MethodsWe searched 32 databases in multiple languages from 1 December 2019 to 27 October 2020. We included randomized trials if they compared any of the drugs of interest to placebo or standard care, or against each other. A related world health organization (WHO) guideline panel selected the interventions to address and identified possible adverse effects that might be important to patients. Pairs of reviewers independently extracted data and assessed risk of bias. We analyzed data using a fixed-effects pairwise meta-analysis and assessed the certainty of evidence using the GRADE approach.ResultsWe included 16 randomized trials which enrolled 8226 patients. Compared to standard care or placebo, low certainty evidence suggests that remdesivir may not have an important effect on acute kidney injury (risk difference [RD] 8 fewer per 1000, 95% confidence interval (CI): 27 fewer to 21 more) or cognitive dysfunction/delirium (RD 3 more per 1000, 95% CI: 12 fewer to 19 more). Low certainty evidence suggests that hydroxychloroquine may increase the risk of serious cardiac toxicity (RD 10 more per 1000, 95% CI: 0 more to 30 more) and cognitive dysfunction/delirium (RD 33 more per 1000, 95% CI: 18 fewer to 84 more), whereas moderate certainty evidence suggests hydroxychloroquine probably increases the risk of diarrhoea (RD 106 more per 1000, 95% CI: 48 more to 175 more) and nausea and/or vomiting (RD 62 more per 1000, 95% CI: 23 more to 110 more) compared to standard care or placebo. Low certainty evidence suggests lopinavir/ritonavir may increase the risk of diarrhoea (RD 168 more per 1000, 95% CI: 58 more to 330 more) and nausea and/or vomiting (RD 160 more per 1000, 95% CI: 100 more to 210 more) compared to standard care or placebo.ConclusionHydroxychloroquine probably increases the risk of diarrhoea and nausea and/or vomiting and may increase the risk of cardiac toxicity and cognitive dysfunction/delirium. Remdesivir may have no effect on risk of acute kidney injury or cognitive dysfunction/delirium. Lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting. These findings provide important information to support the development of evidence-based management strategies for patients with COVID-19.

Effects of immunosuppressive therapy reduction and early post-infection graft function in kidney transplant recipients with COVID-19

“…The different timing of enrollment made the two cohorts not perfectly comparable. The enrollment of all patients of the Brescia cohort during the first wave has probably magnified the risk of side effects of therapeutic regimens administered during the first wave [27,28] and the challenges to delivering the standard of care in an overwhelmed and unprepared hospital. Lastly, a lower age (56.1 vs 60 years) in our cohort of patients has probably contributed to lead to a better prognosis.…”

Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses

“…Despite efforts on many fronts, specific therapeutic approaches to treatment of SARS‐CoV‐2 have yielded variable or no significant benefit compared to standard of care [5–9]. These include remdesivir, immune plasma, monoclonal antibodies against spike protein and anti‐inflammatory agents.…”

Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis

“…On the other hand, Wang's study (21), which was performed based on two studies conducted by Beigel and Wang, founded that the risk of adverse events for remdesivir was significantly lower than the placebo/control. Izcovich et al (2020) also stated that remdesivir might have negligible effects on acute kidney injury and cognitive dysfunction/delirium (28).…”